Program
Anti-TMPRSS6 Monoclonal Antibody DISC-3405
Also written as “DISC-3405” and “9MW3011”.
Its studies are mostly in Polycythemia Vera · Anemia, Sickle Cell · beta-Thalassemia, led by 2 companies.
Drug pageAnti-TMPRSS6 Monoclonal Antibody DISC-3405: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Disc Medicine | 32 open or running | phase 2since May 7, 2025 | Sep 7, 2023 | Jun 2027phase 1 · NCT07187973 |
| Mabwell (Shanghai) Bioscienceits history only | 32 open or running | phase 1since Feb 25, 2024 | Feb 25, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Disc Medicine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2023First study: phase 1 study in Healthy VolunteerFirst studyNCT06050915 · 64 enrolled · United States
- May 7, 2025Phase 2 study in Polycythemia VeraNCT06985147 · 60 enrolled · United States
- Sep 8, 2025Phase 1 study in Anemia, Sickle CellNCT07187973 · 24 planned · United States
Ahead
- Jun 2027Primary completion: phase 1 study in Anemia, Sickle CellNCT07187973
- Jul 2027Primary completion: phase 2 study in Polycythemia VeraNCT06985147
TargetBeta
“A humanized monoclonal antibody directed against transmembrane serine protease 6 (TMPRSS6; matriptase-2), that can potentially be used to regulate TMPRSS6, hepcidin and iron levels and treat iron overload and anemia associated with certain disorders such as polycythemia vera (PV), beta thalassemia, ”NCIt, by rule
Other programs on TMPRSS6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sapablursenrule | Ionis Pharmaceuticals | phase 3 | 4 |
| AG-236rule | Agios Pharmaceuticals | phase 3 | 2 |
Studies
All 3 Disc Medicine leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07187973Anemia, Sickle Cell · United States | 1 | Recruiting | Jun 2027 | 24 |
| NCT06985147Polycythemia Vera · United States | 2 | Active, not recruiting | Jul 2027 | 60 |
| NCT06050915Healthy Volunteer · United States | 1 | Completed | Jul 9, 2024 | 64 |
How it is read
Names in the registry
- “DISC-3405”, 4 entries
- “9MW3011”, 3 entries
Conditions, from the studies’ own filings
- Polycythemia Vera, 2 studies
- Anemia, Sickle Cell, 1 study
- beta-Thalassemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.